Functional Validation of Single Domain Antibody-Derived CD33 Specific CAR-T Cells for the Treatment of Acute Myeloid Leukemia […]
Publication Programs: Platform
ESGCT – 2022 – Poster Presentation P432
Multiplex deletion of myeloid antigens by base editing in human hematopoietic stem and progenitor cells (HSPCs) enables potential for next generation transplant for acute myeloid leukemia (AML) treatment […]
ESGCT – 2022 – Poster Presentation P150
Efficient knockout of both CD33 and CLL-1 by multiplex genome editing of human hematopoietic stem cells enhances the potential of next- generation transplants for acute myeloid leukemia (AML) treatment […]
Bioprocess International – 2022 – Poster Presentation CT11
Automated Closed Cell Processing System De-Risks Gene-Edited CD34+ Hematopoietic Stem Cell Manufacturing […]
Read More… from Bioprocess International – 2022 – Poster Presentation CT11
ISMB – 2022 – Poster Presentation 859
TransACT enhances detection and characterization of translocation events from high-throughput sequencing data at base-pair resolution for gene editing products […]
EHA – 2022 – Poster Presentation 1429
Multiplex Deletion of Myeloid Antigens CD33 and CLL-1 by CRISPR/Cas9 in Human Hematopoietic Stem Cells Highlights the Potential of Next-Generation Transplantation for AML Treatment […]
ASGCT – 2022 – Poster Presentation Tu-117
A Novel Scalable Electroporation Platform for the Manufacturing of Gene Modified Hematopoietic Stem and Progenitor Cell Therapies […]
ISGCT – 2022 – Poster Presentation 933
Novel Automated, Functionally Closed System for Rapid Immunomagnetic Negative Selection of T Cells […]
Keystone Symposia – 2022 – Poster Presentation 3002
Multiplex Editing of Hematopoietic Stem and Progenitor Cells (HSPCs) with CRISPR Cas Nucleases Achieves High On Target Editing with Undetectable Translocations […]
Read More… from Keystone Symposia – 2022 – Poster Presentation 3002